A DPP-4 inhibitor comprising a peptide represented by the formula (1): Xe-Pro/Ala/Hyp-Xa-Xb-Xc-Xd (wherein Xe is an amino acid residue with an isoelectric point of 5.9 to 6.3; Pro/Ala/Hyp represents Pro, Ala, or Hyp; Xa is an amino acid residue other than Hyp, Pro, and Arg, or deletion; Xb is Gly, P
A DPP-4 inhibitor comprising a peptide represented by the formula (1): Xe-Pro/Ala/Hyp-Xa-Xb-Xc-Xd (wherein Xe is an amino acid residue with an isoelectric point of 5.9 to 6.3; Pro/Ala/Hyp represents Pro, Ala, or Hyp; Xa is an amino acid residue other than Hyp, Pro, and Arg, or deletion; Xb is Gly, Pro, or deletion; Xc is Pro, Ala, or deletion; and Xd is an amino acid residue or deletion) as an active component. The inhibitor can be expected to bring out an effect of lowering blood glucose levels by enhancing effects of incretins; and the inhibitor may be used as a therapeutic agent for diabetes and, in addition, can act on the immune system or the like to be thus used in treatment for skin diseases or the like.
대표청구항▼
1. A DPP-4 inhibitor comprising a collagen-derived peptide represented by the formula (1): Xe-Pro/Ala/Hyp-Xa-Xb-Xc-Xd (wherein Xe is an amino acid residue with an isoelectric point of 5.9 to 6.3; Pro/Ala/Hyp represents Pro, Ala, or Hyp; Xa is an amino acid residue other than Hyp, Pro, and Arg, or de
1. A DPP-4 inhibitor comprising a collagen-derived peptide represented by the formula (1): Xe-Pro/Ala/Hyp-Xa-Xb-Xc-Xd (wherein Xe is an amino acid residue with an isoelectric point of 5.9 to 6.3; Pro/Ala/Hyp represents Pro, Ala, or Hyp; Xa is an amino acid residue other than Hyp, Pro, and Arg, or deletion; Xb is Gly, Pro, or deletion; Xc is Pro, Ala, or deletion; and Xd is an amino acid residue or deletion) as an active component, wherein the peptide is an one of:the formula (A-1): Gly-Pro-Xa-Xb-Xc-Xd (wherein Xa is an amino acid residue with an isoelectric point of 3.0 to 6.2 other than Hyp and Val; Xb is Gly; Xc is Pro or deletion; and Xd is an amino acid residue other than Ala or deletion);the formula (A-2): Gly-Ala-Xa-Xb-Xc-Xd (wherein Xa is an amino acid residue with an isoelectric point of 5.8 to 6.2 or deletion; Xb is Gly or deletion; Xc is Pro or deletion; and Xd is an amino acid residue or deletion);the formula (B-1): Leu-Pro-Xa-Xb-Xc (wherein Xa is Gly; Xb is Pro or deletion; and Xc is Ala or deletion);the formula (B-2): Leu/Ile-Hyp-Xa-Xb-Xc (wherein Leu/Ile represents Leu or Ile; Xa is Gly; Xb is Pro or deletion; and Xc is Ala or deletion). 2. (canceled) 3. (canceled) 4. The DPP-4 inhibitor according to any of claim 1, wherein the peptide is any one or more types selected from the group consisting of: Leu-Pro-Gly, Leu-Pro-Gly-Pro-Ala, Ile-Hyp-Gly, Leu-Hyp-Gly-Pro-Ala, Gly-Pro-Ala-Gly, Gly-Pro-Ala-Gly-Pro, Gly-Pro-Ala-Gly-Pro-Arg, Gly-Pro-Ala-Gly-Pro-Hyp, Gly-Pro-Ala-Gly-Pro-Ile, Gly-Pro-Leu-Gly-Pro-Val, Gly-Pro-Ile-Gly-Pro-Val, Gly-Ala-Ile-Gly-Pro-Ala, Gly-Ala-Ile-Gly-Pro-Ser, Gly-Ala-Val-Gly-Pro-Ala, Gly-Ala-Val-Gly-Pro, and Gly-Ala. 5. The DPP-4 inhibitor according to claim 1, wherein the peptide is a mixture of any one or more types represented bythe formula (A-1): Gly-Pro-Xa-Xb-Xc-Xd (wherein Xa is an amino acid residue with an isoelectric point of 3.0 to 6.2 other than Hyp and Val; Xb is Gly; Xc is Pro or deletion; and Xd is an amino acid residue other than Ala or deletion);the formula (A-2): Gly-Ala-Xa-Xb-Xc-Xd (wherein Xa is an amino acid residue with an isoelectric point of 5.8 to 6.2 or deletion; Xb is Gly or deletion; Xc is Pro or deletion; and Xd is an amino acid residue or deletion); withany one or more types represented bythe formula (B-1): Leu-Pro-Xa-Xb-Xc (wherein Xa is Gly; Xb is Pro or deletion; and Xc is Ala or deletion);the formula (B-2): Leu/Ile-Hyp-Xa-Xb-Xc (wherein Leu/Ile represents Leu or Ile; Xa is Gly; Xb is Pro or deletion; and Xc is Ala or deletion).
※ AI-Helper는 부적절한 답변을 할 수 있습니다.